NASDAQ · GOVX
GeoVax Labs, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for GOVX: Nov 12, 2026
GeoVax Labs, Inc. Common Stock is estimated to report earnings on 11/12/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 2 analysts' forecasts, the consensus EPS forecast for the quarter is $-1.02. The reported EPS for the same quarter last year was $-7.75.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-1.02 | $-0.96 | $-1.09 | 2 |
| Dec 2026 | $-1.00 | $-0.81 | $-1.20 | 2 |
| Mar 2027 | $-0.63 | $-0.63 | $-0.63 | 1 |
| Jun 2027 | $-0.66 | $-0.66 | $-0.66 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Fintel · RTTNews · Zacks · MarketBeat- Fintel · Oct 27, 2:28 PM EDTGeoVax Labs, Inc. Stockholders Approve Reverse Stock Split and Issuance of Up to 11,395,256 SharesGeoVax Labs, Inc. held a special meeting of stockholders on October 27, 2026, where stockholders voted on and approved proposals. The company received proxies totaling 4,326,013 of its 9,093,871 issued and outstanding shares of common stock as of the record date of August 28, 202
- Fintel · Oct 27, 12:48 PM EDTGeoVax Labs, Inc. Enters $1,000,000 Revolving Loan Agreement and Reconstitutes BoardGeoVax Labs, Inc. entered into a Revolving Loan Agreement on October 25, 2026, with Bowery Consulting Group Inc. Under the agreement, the company may request loans from time to time in an aggregate principal amount outstanding at any one time not to exceed $1,000,000. Loans under
- RTTNews · Aug 20, 10:38 PM EDTAfter-hours Gainers: HOWL Jumps 90%, MODD To Begin Pivot Pump Rollout, BIVI Awaits Long COVID Data(RTTNews) – The SPDR S&P Biotech ETF (XBI), a broad benchmark for the U.S. biotech sector, fell 3.64% during regular trading Thursday but edged 0.21% higher in after-hours trading. Among the notable biotech gainers in after-hours trading were Werewolf Therapeutics, which is advan
- Zacks · Jun 12, 9:55 AM EDTGeoVax Labs (GOVX) Could Find a Support Soon, Here's Why You Should Buy the Stock NowGeoVax Labs (GOVX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnar
- MarketBeat · May 28, 11:00 AM EDTIs Co-Diagnostics National Security’s Next Diagnostic Pick?A structural shift is underway in the biodefense landscape. The declaration of a Public Health Emergency of International Concern (PHEIC) by the World Health Organization on May 17, 2026, for the Bundibugyo virus Ebola outbreak should be seen by investors as more than a headline
- RTTNews · May 26, 3:50 AM EDTTop Biotech Gainers: AKTX Rallies; GOVX Up On Ebola Concerns; SLGL Awaits Catalysts; CMMB On Watch(RTTNews) – Biotech stocks witnessed strong momentum on Friday, with Akari Therapeutics leading the pack, driven by encouraging preclinical pancreatic cancer data for AKTX-101. MetaVia, GeoVax, Polyrizon, and Sol-Gel were also some of the companies that captured Wall Street's at
- RTTNews · May 21, 10:34 PM EDTBiotech Stock Gainers: CODX Extends Rally, SBFM Surges, GOVX Ebola Strategy, RGNX Awaits Catalysts(RTTNews) – Today's gainers include CODX, which rallied for the third straight day; Akari, on breakthrough clinical data in pancreatic cancer; Sunshine, following regulatory approval for its generic Amoxicillin; GOVX, amid Ebola concerns; and RGNX, on upcoming clinical trial mile
- Zacks · May 15, 12:00 PM EDTAll You Need to Know About GeoVax Labs (GOVX) Rating Upgrade to BuyGeoVax Labs (GOVX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- Fintel · Jan 14, 5:53 AM ESTGeoVax Labs (GOVX) Price Target Increased by 2,400.00% to 237.15The average one-year price target for GeoVax Labs (NasdaqCM:GOVX) has been revised to $237.15 / share. This is an increase of 2,400.00% from the prior estimate of $9.49 dated December 18, 2025. The price target is an average of many targets provided by analyst
- Fintel · Nov 19, 1:03 PM ESTD. Boral Capital Maintains GeoVax Labs (GOVX) Buy RecommendationFintel reports that on November 19, 2025, D. Boral Capital maintained coverage of GeoVax Labs (NasdaqCM:GOVX) with a Buy recommendation. Analyst Price Forecast Suggests 2,375.00% Upside
- Zacks · Aug 20, 12:00 PM EDTGeoVax Labs (GOVX) Upgraded to Buy: What Does It Mean for the Stock?GeoVax Labs (GOVX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- The Motley Fool · Jul 29, 6:34 AM EDTGeoVax Labs Revenue Doubles in Q2– GAAP revenue reached $0.85 million in Q2 2025, exceeding analyst estimates and Revenue more than doubled compared to Q2 2024, also exceeding analyst estimates.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for GeoVax Labs, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.